Spero Therapeutics (SPRO) Other Non-Current Assets (2016 - 2026)
Spero Therapeutics posted quarterly Other Non-Current Assets of $153000.0 for Q1 2026, little changed year-on-year from $153000.0 in Q1 2025, and little changed on a QoQ basis from $153000.0 in Q4 2025.
Spero Therapeutics (SPRO) has 11 years of Other Non-Current Assets data on file, last reported at $153000.0 in Q1 2026.
- For the quarter ending Q1 2026, Other Non-Current Assets changed 0.0% year-over-year to $153000.0; the trailing twelve-month figure through Mar 2026 stood at $153000.0 (changed 0.0% YoY), and the FY2025 full-year result was $153000.0, changed 0.0% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $153000.0, roughly flat from $153000.0 in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $5.9 million in Q1 2022 and bottomed at $153000.0 in Q3 2024.
- The 5-year median for Other Non-Current Assets is $434000.0 (2023), against an average of $2.2 million.
- The widest annual swing landed in 2022, when Other Non-Current Assets advanced 13.76%; it then sank 92.44% in 2024.
- A 5-year view of Other Non-Current Assets shows it stood at $5.7 million in 2022, then slumped by 92.42% to $435000.0 in 2023, then plunged by 64.83% to $153000.0 in 2024, then changed by 0.0% to $153000.0 in 2025, then changed by 0.0% to $153000.0 in 2026.
- The last three Other Non-Current Assets figures came in at $153000.0 (Q1 2026), $153000.0 (Q4 2025), and $153000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 12.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 60,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.26 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 2.13 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 63.55 Mn |
| 10 | Spero Therapeutics | 162.39 Mn | 106.26 Mn | - | 153,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 153,000.00 |
| Dec 31, 2025 | 153,000.00 |
| Sep 30, 2025 | 153,000.00 |
| Jun 30, 2025 | 153,000.00 |
| Mar 31, 2025 | 153,000.00 |
| Dec 31, 2024 | 153,000.00 |
| Sep 30, 2024 | 153,000.00 |
| Jun 30, 2024 | 434,000.00 |
| Mar 31, 2024 | 434,000.00 |
| Dec 31, 2023 | 435,000.00 |
| Sep 30, 2023 | 434,000.00 |
| Jun 30, 2023 | 5.74 Mn |
| Mar 31, 2023 | 5.74 Mn |
| Dec 31, 2022 | 5.74 Mn |
| Sep 30, 2022 | 5.74 Mn |
| Jun 30, 2022 | 5.47 Mn |
| Mar 31, 2022 | 5.93 Mn |
| Dec 31, 2021 | 5.64 Mn |
| Sep 30, 2021 | 5.21 Mn |
| Jun 30, 2021 | 5.21 Mn |
| Mar 31, 2021 | 5.21 Mn |
| Dec 31, 2020 | 5.21 Mn |
| Sep 30, 2020 | 5.21 Mn |
| Jun 30, 2020 | 5.08 Mn |
| Mar 31, 2020 | 4.74 Mn |
| Dec 31, 2019 | 3.52 Mn |
| Sep 30, 2019 | 2.08 Mn |
| Jun 30, 2019 | 2.45 Mn |
| Mar 31, 2019 | 1.42 Mn |
| Dec 31, 2018 | 1.66 Mn |
| Sep 30, 2018 | 206,000.00 |
| Jun 30, 2018 | 206,000.00 |
| Mar 31, 2018 | 206,000.00 |
| Dec 31, 2017 | 50,000.00 |
| Sep 30, 2017 | 50,000.00 |
| Dec 31, 2016 | 206,000.00 |